Nota de idioma: o chrome desta página está em português; o corpo longo abaixo permanece em inglês para preservar a precisão das fontes.
Retatrutide
Also indexed as LY3437943 · triple agonist
Retatrutide is an investigational single molecule designed to activate GIP, GLP-1 and glucagon receptors. Its phase 2 record is interesting; its status is still the key fact to carry forward.
Last reviewed 2026-09-07 · education only
O que aparece na literatura
The three-receptor profile is the mechanism-level idea: incretin-related signaling plus glucagon-receptor activity. Mechanistic elegance does not equal approval, routine care or a verified product.
History & development
- 2023
A phase 2 randomized obesity trial in the New England Journal of Medicine reported dose-ranging results for retatrutide.
Source: NEJM retatrutide phase 2 ↗
- 2026
Lilly's public development update still describes retatrutide as investigational and legally available only to clinical-trial participants.
Source: Eli Lilly development update ↗
Approved brands & pathway
Retatrutide is presented for research-name and evidence literacy. A research name does not authenticate a product or establish a human-use pathway.
Entradas de evidência
Tema: Obesity · triple agonist · Categoria: Obesity
Retatrutide
O que a fonte sustenta
Early phase 2 clinical research
A phase 2 obesity study reported dose-ranging weight outcomes for retatrutide, an investigational triple agonist.
Limite: Investigational status, limited duration and protocol-specific safety mean this is not approval, routine-care guidance or a material-quality finding.
Fonte: Retatrutide phase 2 · NEJM Ler fonte ↗
Grade mix in this atlas
Grades describe the cited record for a narrow question. They do not score a marketplace material or make a health decision.
Naming curiosities & useful distinctions
- Retatrutide is often described as a triple agonist because of its three receptor targets.
- A development code such as LY3437943 is a research identity, not an approved brand.
Status is part of the story
The most important label on this page is investigational. A promising trial record and an approved product pathway are different kinds of facts.
Nomes no registro
Developer
Eli Lilly and Company
Lilly is the developer named in the clinical and company records cited here.